Vincristine sulfate
Vincristine sulfate is an antitumor vinca alkaloid which inhibits microtubule formation in mitotic spindle, resulting in an arrest of dividing cells at the metaphase stage. It binds to microtubule with a Ki of 85 nM.
Inquire / Order:
manager@chemfaces.com
Technical Inquiries:
service@chemfaces.com
Tel:
+86-27-84237783
Fax:
+86-27-84254680
Address:
1 Building, No. 83, CheCheng Rd., Wuhan Economic and Technological Development Zone, Wuhan, Hubei 430056, PRC
Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to
24 months(2-8C).
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com
The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
Korean J of Pharmacognosy2020, 51,49-54.
Enzyme Microb Technol.2019, 122:64-73
In Vitro Cellular & Developmental Biology - Plant2022, 58:972-988.
Pharmacia2022, 69(3): 883-890.
South African Journal of Botany2021, 142:114-123.
Korean J. Food Sci. & Technol.2022, 54(2):241-246
J Nat Med.2020, 74(3):550-560.
Preprints2022, 202211.0388.v1.
Front Chem.2024, 12:1385844.
TCI CO.2019, US20190151257A1
Related and Featured Products
Int J Nanomedicine. 2015 Apr 22;10:3081-95.
Delivery of vincristine sulfate-conjugated gold nanoparticles using liposomes: a light-responsive nanocarrier with enhanced antitumor efficiency.[Pubmed:
25960649]
The present study explored the use of drug-gold nanoparticle conjugates incorporated into liposomes to enhance antitumor efficiency. A model drug, Vincristine sulfate, was physically conjugated with gold nanoparticles and verified by UV-visible and fourier transform infrared spectroscopy, and differential scanning calorimetry.
METHODS AND RESULTS:
The conjugates were incorporated into liposomes by film dispersion to yield nanoparticles (113.4 nm) with light-responsive release properties, as shown by in vitro release studies. Intracellular uptake and distribution was studied in HeLa cells using transmission electron microscopy and confocal laser scanning microscopy. This demonstrated liposome internalization and localization in endosomal-lysosomal vesicles. Fluorescence intensity increased in cells exposed to UV light, indicating that this stimulated intracellular drug release; this finding was confirmed by quantitative analyses using flow cytometry.
Antitumor efficacy was evaluated in HeLa cells, both in culture and in implants in vivo in nude mice.
CONCLUSIONS:
HeLa cell viability assays showed that light exposure enhanced liposome cytotoxicity and induction of apoptosis. Furthermore, treatment with the prepared liposomes coupled with UV light exposure produced greater antitumor effects in nude mice and reduced side effects, as compared with free Vincristine sulfate.
Vet Clin Pathol. 2013 Dec;42(4):458-64.
Erythrocyte dysplasia in peripheral blood smears from 5 thrombocytopenic dogs treated with vincristine sulfate.[Pubmed:
24138476]
Secondary dyserythropoiesis has been associated with vincristine administration in dogs. Evaluation of bone marrow aspirates for the presence of morphologic abnormalities in the erythroid lineage aids in the diagnosis. However, morphologic features of circulating erythroid precursors in these cases have not been described previously. The purpose of this report was to describe the cytologic features of dyserythropoiesis in peripheral blood and also bone marrow smears in a case series of dogs with immune-mediated thrombocytopenia (IMT) treated with Vincristine sulfate.
Clin Lymphoma Myeloma Leuk. 2014 Jun;14(3):197-202.
High-dose vincristine sulfate liposome injection (Marqibo) Is not associated with clinically meaningful hematologic toxicity.[Pubmed:
24417913]
Vincristine sulfate liposome injection at its approved dose resulted in a low incidence of clinically meaningful hematologic toxicity. A near doubling of the median dose density did not have an identifiable effect on the reported incidence and severity of hematologic AEs. Vincristine sulfate liposome injection could be well suited for use combined with myelosuppresive drugs and for patients unable to tolerate peripheral blood cytopenia.
J Drug Target. 2014 Jul;22(6):509-17.
Preparation of vincristine sulfate-loaded poly (butylcyanoacrylate) nanoparticles modified with pluronic F127 and evaluation of their lymphatic tissue targeting.[Pubmed:
24625287]
In order to improve the lymphatic targeting efficiency of anti-cancer agent Vincristine sulfate (VCR), the poly (butylcyanoacrylate) nanoparticles (VCR-PBCA-NPs) were prepared by emulsion polymerization and modified superficially with Pluronic F127.
METHODS AND RESULTS:
These prepared nanoparticles with (F127-VCR-PBCA-NPs) and without surface modification (VCR-PBCA-NPs) were characterized and their lymphatic targeting efficiencies were evaluated in vitro and in vivo. The results showed that Vincristine sulfate was released more sustained from both kinds of Vincristine sulfate-loaded nanoparticles, compared with the Vincristine sulfate solution. The up-taking efficiency of Vincristine sulfate into raji cells was enhanced by F127-VCR-PBCA-NPs, compared with the VCR-PBCA-NPs or Vincristine sulfate solution. Lower clearance (CL) of Vincristine sulfate from the systemic circulation and higher lymphatic targeting efficiency of Vincristine sulfate were observed for F127-VCR-PBCA-NPs than the VCR-PBCA-NPs or Vincristine sulfate solution, and F127-VCR-PBCA-NPs showed greater antitumor efficacy than the VCR-PBCA-NPs or Vincristine sulfate solution in the human Burkitt's lymphoma (raji)-bearing nude mice.
CONCLUSIONS:
These findings suggest that superficially modified nanoscale carriers might be promising vehicles for chemotherapeutic agents in the treatments of metastatic tumors and malignant lymphoma.
